AGNETIC Resonance Imaging (MRI) has been extensively explored as a versatile platform for routine medical and biological imaging with a high degree of spatial resolution, excellent soft tissue contrast and absence of radiation risk. Generally, the MRI contrast originates due to the signal intensity of the imaging sample, produce from magnetization of the protons. The degree of magnetization is determined by the properties of the imaging sample with the applied pulse sequence and applied magnetic field strength [1]. However, the nature of insufficient inherent sensitivity at the small clinical diagnostic targets in complex tissue environments requires the application of MRI contrast agents for better pathological delineation and precise diagnosis [2]-[4].

MRI contrast agents are substances which can alter the tissue relaxation thereby affecting the contrast enhancement [1]. A number of contrast agents have been currently available in the clinical and biological settings. Their efficacy is determined based on the magnetic properties, pharmacokinetics properties (bio-distribution) and the dominant effects of the agent at the image enhancement [2],[4]-[6].